Latest Financial Results News

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Knosys Limited reported a 4.6% revenue increase to $5.07 million for the half-year ending December 2025, driven by stronger licence and project fees. However, the company’s net loss widened significantly to $1.53 million, reflecting heavy investment in its next-generation Libero X library management system.

Sports Entertainment Group reports a robust first half FY26 with nearly doubling EBITDA and declares special dividends following asset sales.

Atturra Limited confirms its FY26 revenue and EBITDA guidance, acknowledging a contract termination impact in H1 but optimistic about a stronger second half.

IDT Australia Limited has reported a significant narrowing of its half-year loss to $1.3 million, driven by stable revenues and operational efficiencies. The pharmaceutical manufacturer highlights growth in key segments despite some timing setbacks.

Solvar Limited reported a 5.8% rise in half-year NPAT to $20 million, driven by the sale of its New Zealand written-off loan book and expanded debt facilities. The company also announced a special dividend and outlined growth plans in commercial lending.

Solvar Limited reported a 5.8% rise in net profit for the half year ending December 2025, driven by strategic asset sales and expanded funding facilities. The company declared both interim and special dividends, signalling confidence despite ongoing regulatory challenges.

Servcorp has reported a robust first half for FY2026, with underlying profit soaring 34% and a strong dividend declared, signalling sustained momentum despite economic uncertainties.

Schaffer Corporation Limited reported a significant 61% drop in net profit and a 17% decline in revenue for the half-year ended December 2025, impacted by operational disruptions and softer market conditions. Despite the downturn, the company declared a fully franked interim dividend of 45 cents per share.

Hearts and Minds Investments Limited reported a dramatic 97% drop in half-year comprehensive income to $3 million, with a largely flat investment portfolio and a significant write-down of Corporate Travel Management shares. Despite this, the company declared a fully franked interim dividend of 9.5 cents per share.

Lycopodium Limited reports strong half-year results for 1H FY26, driven by increased project delivery and strategic expansion into the Americas. The company updates its full-year guidance amid a robust pipeline across gold, copper, and critical minerals.